STOK
Price
$24.74
Change
+$0.79 (+3.30%)
Updated
Oct 9 closing price
Capitalization
1.65B
31 days until earnings call
Intraday BUY SELL Signals
TCRT
Price
$0.79
Change
+$0.01 (+1.28%)
Updated
Oct 9 closing price
Capitalization
2.59M
Intraday BUY SELL Signals
Interact to see
Advertisement

STOK vs TCRT

STOK vs TCRT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
STOK vs. TCRT commentary
Oct 11, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is STOK is a Hold and TCRT is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
STOK vs TCRT: Fundamental Ratings
STOK
TCRT
OUTLOOK RATING
1..100
5950
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
8296
P/E GROWTH RATING
1..100
3100
SEASONALITY SCORE
1..100
3750

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TCRT's Valuation (68) in the Biotechnology industry is in the same range as STOK (84) in the null industry. This means that TCRT’s stock grew similarly to STOK’s over the last 12 months.

TCRT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as STOK (100) in the null industry. This means that TCRT’s stock grew similarly to STOK’s over the last 12 months.

STOK's SMR Rating (98) in the null industry is in the same range as TCRT (100) in the Biotechnology industry. This means that STOK’s stock grew similarly to TCRT’s over the last 12 months.

STOK's Price Growth Rating (82) in the null industry is in the same range as TCRT (96) in the Biotechnology industry. This means that STOK’s stock grew similarly to TCRT’s over the last 12 months.

STOK's P/E Growth Rating (3) in the null industry is significantly better than the same rating for TCRT (100) in the Biotechnology industry. This means that STOK’s stock grew significantly faster than TCRT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
STOKTCRT
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 10 days ago
89%
Bullish Trend 19 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 11, 2026
Stock price -- (STOK: $24.74 vs. TCRT: $0.79)
Brand notoriety: STOK and TCRT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: STOK: 58% vs. TCRT: 7%
Market capitalization -- STOK: $1.65B vs. TCRT: $2.59M
STOK [@Biotechnology] is valued at $1.65B. TCRT’s [@Biotechnology] market capitalization is $2.59M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

STOK’s FA Score shows that 1 FA rating(s) are green while TCRT’s FA Score has 0 green FA rating(s).

  • STOK’s FA Score: 1 green, 4 red.
  • TCRT’s FA Score: 0 green, 5 red.
According to our system of comparison, STOK is a better buy in the long-term than TCRT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

STOK’s TA Score shows that 4 TA indicator(s) are bullish while TCRT’s TA Score has 4 bullish TA indicator(s).

  • STOK’s TA Score: 4 bullish, 3 bearish.
  • TCRT’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, TCRT is a better buy in the short-term than STOK.

Price Growth

STOK (@Biotechnology) experienced а -3.43% price change this week, while TCRT (@Biotechnology) price change was -4.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.51%. For the same industry, the average monthly price growth was -13.43%, and the average quarterly price growth was -4.26%.

Reported Earning Dates

STOK is expected to report earnings on Nov 10, 2026.

Industries' Descriptions

@Biotechnology (-2.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.